CAR T cells for solid tumors – developments to watch in 2023

References

• Michaelides S, Obeck H, Kechur D, et al. Migratory engineering of T cells for cancer therapy. Vaccines. 2022;10(11):1845. doi: 10.3390/VACCINES10111845
   Web of Science ®Google Scholar
• Lesch S, Benmebarek MR, Cadilha BL, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2020;65:80–90. doi: 10.1016/j.semcancer.2019.11.004
   PubMed Web of Science ®Google Scholar
• Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science (1979). 2020;367(6476):446–453. doi: 10.1126/science.aay5967
   PubMed Web of Science ®Google Scholar
• Mackensen A, Haanen JBAG, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844–2853. doi: 10.1038/s41591-023-02612-0
   PubMed Web of Science ®Google Scholar
• Li D, Guo X, Yang K, et al. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721. doi: 10.1126/sciadv.adg9721
   PubMed Web of Science ®Google Scholar
• Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–941.
   PubMed Web of Science ®Google Scholar
• Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284–1295. doi: 10.1056/NEJMoa2210859
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou J, Yang X, et al. Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22(1):1–15. doi: 10.1186/s12943-022-01711-9
   PubMed Web of Science ®Google Scholar
• Björk JR, Bolte LA, Maltez Thomas A, et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nature Medicine 2024. 2024;1–12. Published online February 16. doi: 10.1038/s41591-024-02803-3
   Google Scholar
• Stein-Thoeringer CK, Saini NY, Zamir E, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29(4):906–916.
   PubMed Web of Science ®Google Scholar
• Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science (1979). 2020;368(6494):973–980. doi: 10.1126/SCIENCE.AAY9189/
   PubMed Web of Science ®Google Scholar
• Vincent RL, Gurbatri CR, Li F, et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science (1979). 2023;382(6667):211–218. doi: 10.1126/science.add7034
   Web of Science ®Google Scholar
• Hong Y, Walling BL, Kim HR, et al. ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors. Nat Immunol. 2023;24(6):1007–1019.
   PubMed Web of Science ®Google Scholar
• Tousley AM, Rotiroti MC, Labanieh L, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507–516.
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):7378. doi: 10.1126/scitranslmed.abe7378
   Web of Science ®Google Scholar
• Jain N, Zhao Z, Feucht J, et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. 2023;615(7951):315–322.
   PubMed Web of Science ®Google Scholar
• Gottschlich A, Thomas M, Grünmeier R, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023;41(11):1618–1632. doi: 10.1038/s41587-023-01684-0
   PubMed Web of Science ®Google Scholar
• Yang J, Chen Y, Jing Y, et al. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol. 2023 4 20;20(4):211–228.
   PubMed Web of Science ®Google Scholar
• Rejeski K, Perez A, Iacoboni G, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022;10(5):e004475. doi: 10.1136/JITC-2021-004475
   PubMed Web of Science ®Google Scholar
• Skovgard MS, Hocine HR, Saini JK, et al. Imaging CAR T-cell kinetics in solid tumors: translational implications. Mol Ther Oncolytics. 2021;22:355–367. doi: 10.1016/J.OMTO.2021.06.006
   PubMed Web of Science ®Google Scholar
• Uslu U, Da T, Assenmacher CA, et al. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Sci Adv. 2023;9(2). doi: 10.1126/sciadv.ade2526
   PubMed Web of Science ®Google Scholar
• Di Pilato M, Kfuri-Rubens R, Pruessmann JN, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184(17):4512–4530.e22.
   PubMed Web of Science ®Google Scholar
• Cadilha BL, Benmebarek MR, Dorman K, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021;7(24):5781–5790. doi: 10.1126/sciadv.abi5781
   Web of Science ®Google Scholar
• FDA investigating serious risk of T-cell malignancy following BCMA-Directed or CD19-directed autologous Chimeric Antigen Receptor (CAR) T cell immunotherapies | FDA. [cited 2024 Jan 23]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous
   Google Scholar